Skandinaviska Enskilda Banken AB publ Lowers Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Key Points

• Skandinaviska Enskilda Banken AB publ reduced its holdings in Janux Therapeutics by 13.3%, selling 27,347 shares and now holding 177,820 shares worth approximately $4.8 million.
• Institutional investors currently own 75.39% of Janux Therapeutics, with notable increases in holdings by firms such as GAMMA Investing LLC, which lifted its stake by 1,574.0% during the first quarter.
• Janux's stock performance shows a market cap of $1.54 billion with a 52-week range between $22.48 and $71.71, and analysts have an average price target of $91.89.

Skandinaviska Enskilda Banken AB publ lowered its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 13.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 177,820 shares of the company's stock after selling 27,347 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.30% of Janux Therapeutics worth $4,801,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after purchasing an additional 1,574 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after acquiring an additional 442 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Janux Therapeutics during the 4th quarter worth $59,000. FNY Investment Advisers LLC lifted its position in shares of Janux Therapeutics by 6,928.6% during the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after buying an additional 2,425 shares in the last quarter. Finally, KBC Group NV purchased a new stake in Janux Therapeutics during the first quarter worth about $66,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Stock Down 0.4%

NASDAQ:JANX traded down $0.10 during trading hours on Wednesday, hitting $24.08. 323,889 shares of the company's stock traded hands, compared to its average volume of 943,843. The business's fifty day simple moving average is $24.80 and its two-hundred day simple moving average is $30.00. Janux Therapeutics, Inc. has a 52 week low of $22.48 and a 52 week high of $71.71. The firm has a market cap of $1.42 billion, a P/E ratio of -17.71 and a beta of 2.86.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. On average, analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Analyst Ratings Changes

Separately, Raymond James Financial initiated coverage on Janux Therapeutics in a report on Friday, July 11th. They set an "outperform" rating and a $65.00 price objective for the company. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Janux Therapeutics presently has an average rating of "Buy" and an average target price of $91.89.

Insider Activity

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the completion of the sale, the insider directly owned 82,139 shares in the company, valued at $2,630,912.17. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 29.40% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.